- Home
- GBX vs BEAM Comparison
GBX vs BEAM Comparison
Compare GBX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- BEAM
- Stock Information
- Founded
- GBX 1974
- BEAM 2017
- Country
- GBX United States
- BEAM United States
- Employees
- GBX N/A
- BEAM N/A
- Industry
- GBX Railroads
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBX Industrials
- BEAM Health Care
- Exchange
- GBX Nasdaq
- BEAM Nasdaq
- Market Cap
- GBX 1.8B
- BEAM 1.6B
- IPO Year
- GBX N/A
- BEAM 2020
- Fundamental
- Price
- GBX $45.71
- BEAM $16.76
- Analyst Decision
- GBX Hold
- BEAM Strong Buy
- Analyst Count
- GBX 2
- BEAM 11
- Target Price
- GBX $57.00
- BEAM $48.90
- AVG Volume (30 Days)
- GBX 196.6K
- BEAM 1.8M
- Earning Date
- GBX 07-07-2025
- BEAM 08-05-2025
- Dividend Yield
- GBX 2.81%
- BEAM N/A
- EPS Growth
- GBX 85.75
- BEAM N/A
- EPS
- GBX 6.26
- BEAM N/A
- Revenue
- GBX $3,511,200,000.00
- BEAM $63,578,000.00
- Revenue This Year
- GBX N/A
- BEAM N/A
- Revenue Next Year
- GBX N/A
- BEAM $8.82
- P/E Ratio
- GBX $7.27
- BEAM N/A
- Revenue Growth
- GBX N/A
- BEAM N/A
- 52 Week Low
- GBX $37.77
- BEAM $13.53
- 52 Week High
- GBX $71.06
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- GBX 51.11
- BEAM 44.29
- Support Level
- GBX $44.90
- BEAM $16.18
- Resistance Level
- GBX $46.24
- BEAM $18.33
- Average True Range (ATR)
- GBX 0.84
- BEAM 1.10
- MACD
- GBX -0.02
- BEAM 0.00
- Stochastic Oscillator
- GBX 54.61
- BEAM 28.65
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.